Synapse Open Synapse
AI

OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

The Decoder · · 1 min read

OpenAI is acquiring startup Orchestra Bio and plans to merge it with its life sciences AI platform Rosalind. The goal is to build AI agents that help pharma teams coordinate drug development, from tracking trials to spotting problems. Developing a new drug in the US takes ten to 15 years on average.

Latest from The Decoder